Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Operating Expenses: 2011-2025

Historic Other Operating Expenses for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $1.3 million.

  • Adma Biologics' Other Operating Expenses rose 24.88% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 21.51%. This contributed to the annual value of $4.6 million for FY2024, which is 7.15% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Other Operating Expenses is $1.3 million, which was up 10.64% from $1.2 million recorded in Q2 2025.
  • Adma Biologics' Other Operating Expenses' 5-year high stood at $5.3 million during Q4 2022, with a 5-year trough of $646,000 in Q3 2023.
  • Moreover, its 3-year median value for Other Operating Expenses was $1.2 million (2024), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Adma Biologics' Other Operating Expenses surged by 110.58% in 2021, and later crashed by 87.18% in 2023.
  • Quarterly analysis of 5 years shows Adma Biologics' Other Operating Expenses stood at $4.3 million in 2021, then grew by 23.16% to $5.3 million in 2022, then tumbled by 83.44% to $872,000 in 2023, then surged by 49.31% to $1.3 million in 2024, then rose by 24.88% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.2 million for Q2 2025, and $1.3 million during Q1 2025.